We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+13.92%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$104M
Cap. Flow
-$16.3M
Cap. Flow %
-0.99%
Top 10 Hldgs %
51.14%
Holding
80
New
16
Increased
18
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.2M
2
ABBV icon
AbbVie
ABBV
+$49.4M
3
BSX icon
Boston Scientific
BSX
+$43.6M
4
UTHR icon
United Therapeutics
UTHR
+$35.4M
5
LLY icon
Eli Lilly
LLY
+$34.4M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$111M
2
MDT icon
Medtronic
MDT
+$50.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.6M
4
BPMC
Blueprint Medicines
BPMC
+$23.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
AstraZeneca
AZN
$263B
$20.5M 1.26%
+146,831
New +$20.6M
PTCT icon
27
PTC Therapeutics
PTCT
$6.37B
$18.4M 1.12%
375,939
-203,400
-35% -$9.66M
INZY
28
DELISTED
Inozyme Pharma
INZY
$17.1M 1.05%
4,280,308
– –
COGT icon
29
Cogent Biosciences
COGT
$6.79B
$16.9M 1.03%
2,355,505
+173,384
+8% +$961K
REPL icon
30
Replimune Group
REPL
$814M
$16.8M 1.03%
1,806,529
-673,410
-27% -$5.88M
RNAM
31
DELISTED
Avidity Biosciences
RNAM
$16.6M 1.02%
584,801
+204,870
+54% +$6.11M
SMMT icon
32
CALL
Summit Therapeutics
SMMT
$10.9B
$14.9M 0.91%
+700,000
New +$16M
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.84B
$14.3M 0.87%
1,524,440
-750,783
-33% -$8.26M
RYTM icon
34
PUT
Rhythm Pharmaceuticals
RYTM
$7B
$14.2M 0.87%
+225,000
New +$13.8M
REPL icon
35
PUT
Replimune Group
REPL
$814M
$13.9M 0.85%
+1,500,000
New +$13.1M
CDTX
36
DELISTED
Cidara Therapeutics
CDTX
$12.2M 0.75%
+251,031
New +$6.03M
IMTX icon
37
Immatics
IMTX
$1.24B
$12.1M 0.74%
2,240,528
+686,224
+44% +$3.4M
ROIV icon
38
CALL
Roivant Sciences
ROIV
$25.2B
$11.3M 0.69%
+1,000,000
New +$10.8M
EXAS
39
DELISTED
Exact Sciences
EXAS
$11.1M 0.68%
+208,300
New +$10.6M
PHVS icon
40
Pharvaris
PHVS
$2.39B
$10.3M 0.63%
585,532
-7,871
-1% -$127K
INBX icon
41
Inhibrx
INBX
$1.2B
$10.1M 0.62%
708,678
+10,762
+2% +$139K
RCUS icon
42
Arcus Biosciences
RCUS
$3.57B
$9.9M 0.61%
1,216,016
+178,240
+17% +$1.52M
YMAB
43
DELISTED
Y-mAbs Therapeutics
YMAB
$9.9M 0.61%
2,194,278
– –
AXSM icon
44
Axsome Therapeutics
AXSM
$12.4B
$9.77M 0.6%
93,610
-81,707
-47% -$8.65M
BIOA
45
BioAge Labs
BIOA
$968M
$9.52M 0.58%
2,304,901
– –
EWTX icon
46
Edgewise Therapeutics
EWTX
$4.39B
$9.4M 0.57%
716,873
+374,655
+109% +$5.4M
IMNM icon
47
Immunome
IMNM
$2.52B
$7.24M 0.44%
778,476
-10,190
-1% -$83.5K
DYN icon
48
Dyne Therapeutics
DYN
$4.04B
$5.85M 0.36%
614,865
-102,031
-14% -$1.12M
SVRA icon
49
Savara
SVRA
$1.13B
$5.6M 0.34%
2,457,352
-3,024,314
-55% -$8.23M
CDTX
50
CALL
DELISTED
Cidara Therapeutics
CDTX
$4.87M 0.3%
+100,000
New +$2.4M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Sofinnova Investments held 80 positions worth $1.64B, up 6.8% from $1.53B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments's Q2 2025 filing shows 16 new, 18 increased, 19 reduced and 17 closed positions. Its largest new stake was AbbVie: 265,850 shares worth $49.3M. The largest sale was Stryker, an estimated $111M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

  • Sofinnova Investments's largest Q2 2025 buy was AbbVie: 265,850 shares worth $49.3M.
  • Sofinnova Investments added most to Gilead Sciences in Q2 2025, an estimated $67.2M increase.
  • Sofinnova Investments's biggest Q2 2025 reduction was PTC Therapeutics, cutting an estimated $9.66M.
  • Sofinnova Investments fully exited Stryker in Q2 2025, selling an estimated $111M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.64B portfolio in Q2 2025.
  • Sofinnova Investments opened 16 new positions and closed 17 in Q2 2025.
  • Sofinnova Investments's portfolio value rose 6.8% quarter-over-quarter to $1.64B.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.